TA-316

• Description :

  TA-3166 (Megakaryocytes/platelets inducing agent) is a novel chemically synthesized c-MPL agonist (CMA) and thrombopoietin (TPO) receptor agonist. TA-316 enhances ex vivo platelet generation from human-induced pluripotent stem (iPS) cells[1][2].

• Product Name Alternative :

  Megakaryocytes/platelets inducing agent

• UNSPSC :

  12352005

• Hazard Statement :

  H303, H315, H319, H335

• Target :

  Cyclin G-associated Kinase (GAK)

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Neuroscience-Neurodegeneration

• Field of Research :

  Cardiovascular Disease

• Assay Protocol :

  https://www.medchemexpress.com/Megakaryocytes-platelets_inducing_agent.html

• Purity :

  99.50

• Solubility :

  DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles :

  O=C(C1=CC=C(C(NCC2=CC=C(C(NCCO)=O)C=C2)=O)S1)N/N=C(C3=CSC(C4=CC=C(Br)C=C4)=C3O)\C

• Molecular Formula :

  C28H25BrN4O5S2

• Molecular Weight :

  641.56

• Precautions :

  H303, H315, H319, H335

• References & Citations :

  [1]METHOD FOR PRODUCING MEGAKARYOCYTES AND/OR PLATELETS FROM PLURIPOTENT STEM CELLS.WO2013051625A1.|[2]Aihara A, et al. Novel TPO receptor agonist TA-316 contributes to platelet biogenesis from human iPS cells. Blood Adv. 2017;1 (7) :468-476. Published 2017 Feb 28.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [1429321-13-0]